智通财经APP讯，威高股份(01066)发布公告，该公司于2025年12月18日斥资31.38万港元回购6万股股 份，每股回购价格为5.23港元。 ...

威高股份(01066)发布公告，该公司于2025年12月18日斥资31.38万港元回购6万股股份，每股回购价格为 5.23港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年12月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存 ...

Core Insights - The global life support medical device market is projected to reach $75.1 billion in 2024 and is expected to exceed $80 billion in 2025, with a potential to surpass $100 billion in the next five years [3][5] - The domestic life support medical device market in China is rapidly growing, with an estimated market size of 55.7 billion yuan in 2024, expected to reach 61.95 billion yuan in 2025, and potentially reaching 93.2 billion yuan in the next five years [5] Industry Definition and Classification - Life support medical devices are critical equipment used to replace or assist the function of vital organs in emergency situations, primarily utilized in ICUs, emergency rooms, operating rooms, and pre-hospital care [2][3] - Key categories of life support medical devices include blood purification equipment, monitors, ventilators, anesthesia machines, ECG machines, defibrillators, and CPR devices [2][3] Current Industry Development - The life support medical device sector is characterized by high-risk equipment that plays a crucial role in medical rescue and care [3] - The industry has seen rapid market expansion, with significant growth expected in the coming years [3][5] Industry Chain - The upstream of the life support medical device industry includes raw materials, electronic components, biological materials, high-performance batteries, precision sensors, packaging materials, and software systems [5] - The midstream focuses on the research and manufacturing of life support medical devices, while the downstream includes medical institutions, home users, and rehabilitation centers [5] Competitive Landscape - The life support medical device market is marked by high technical barriers and growth potential, with leading domestic companies including Mindray, Yuyue Medical, and Weigao [7] - The market is relatively concentrated, with foreign companies dominating the high-end segment while domestic brands are making breakthroughs in the mid-to-low end and advancing towards high-end products [7] Development Trends - The life support medical device industry is increasingly recognized as essential in modern medicine, with a focus on integrated, precise, and intelligent technologies [10] - The demand for life support medical devices is expected to grow due to the aging population and the rising need for critical care related to severe and emergency patients [10]

Core Viewpoint - Weigao Group (01066.HK) announced a share buyback on December 17, 2025, spending HKD 1.7479 million to repurchase 340,800 shares at a price range of HKD 5.11 to 5.15 per share [1] Summary by Category - **Company Actions** - Weigao Group executed a share buyback, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 1.7479 million [1] - The number of shares repurchased was 340,800 [1] - The buyback price per share ranged from HKD 5.11 to HKD 5.15 [1]

Group 1 - The company, Weigao Group (01066), announced a share buyback plan on December 17, 2025, involving an expenditure of HKD 1.7479 million to repurchase 340,800 shares [1] - The buyback price is set between HKD 5.11 and HKD 5.15 per share [1]

Core Viewpoint - Weigao Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - Weigao Co., Ltd. plans to repurchase 340,800 shares at a total cost of HKD 1.7479 million [1] - The buyback price is set between HKD 5.11 and HKD 5.15 per share [1]

公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年12月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行 ...

Core Viewpoint - Weigao Group (01066) announced a share buyback plan, intending to repurchase 426,000 shares for a total cost of HKD 2.193 million [1] Group 1 - The company will execute the buyback on December 16, 2025 [1] - The total number of shares to be repurchased is 426,000 [1] - The total expenditure for the buyback is HKD 2.193 million [1]

Core Viewpoint - Weigao Group (01066) announced a share buyback plan, intending to repurchase 426,000 shares at a cost of HKD 2.193 million, scheduled for December 16, 2025 [1] Summary by Category - **Company Actions** - Weigao Group plans to spend HKD 2.193 million to buy back 426,000 shares [1]